Page 29 - Astrazeneca

Covid-19: Indian sites await DCGI nod to restart Oxford vaccine trial

The Drug Controller General of India (DCGI) V G Somani will take a call after he receives data from the Data and Safety Monitoring Board (DSMB) in the UK as well as India

AstraZeneca's pause on Covid-19 vaccine trial a 'wake-up call', says WHO

"This is a wake-up call to recognise that there are ups and downs in clinical development and that we have to be prepared," Soumya Swaminathan told a virtual briefing from Geneva

Covid-19: Serum Institute puts Oxford vaccine's India trials on hold

Serum Institute of India (SII) on Thursday said it is pausing clinical trials of AstraZeneca Oxford COVID-19 vaccine candidate in the country. Earlier this week, AstraZeneca said it had paused the trials because of 'an unexplained illness' in a participant in the study. However, SII on Wednesday said it was continuing with the trials and had not faced any issues. SII's latest announcement also comes against the backdrop of the central drug regulator DCGI issuing a show-cause notice to SII for not informing it about AstraZeneca pausing the clinical trials of the Oxford vaccine candidate in other countries. "We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials," SII said in a statement. The Pune-based vaccine maker also said it is following instructions of the Drugs Controller General of India (DCGI), it added. In the show-cause notice, DCGI V G Somani had asked SII as to why the permission granted for conducting phase 2 and 3 clinical trial

Serum Institute puts India trials of AstraZeneca's Covid-19 vaccine on hold

Serum Institute of India has put trials of AstraZeneca's Covid-19 vaccine candidate on hold until the British drugmaker restarts the trials, Serum said

India's single-day spike, Trump downplaying virus, FB's anti-vaxxer posts

On Wednesday, Maharashtra and Delhi recorded their highest single-day spike of 23,816 and 4,039 cases, respectively

Covid-19: Serum Institute to halt trial of Oxford vaccine after DCGI notice

On Tuesday, AstraZeneca had decided to stop trials after a participant fell sick with an unexplained illness.

DCGI issues notice to Serum Institute over Oxford's Covid trial suspension

The DGCI sought an immediate reply saying else "it shall be construed that you have no explanation to offer and action deemed fit will be taken against you"

Fauci says Astrazeneca vaccine pause unfortunate but a safety valve

Anthony Fauci said that AstraZeneca's decision to pause global trials of its coronavirus vaccine was unfortunate but not an uncommon safety precaution in a vaccine development process

AstraZeneca Pharma shares dip over 3% after it halts Covid vaccine trials

Shares of AstraZeneca Pharma, closed over 3 per cent lower on Wednesday after its Covid-19 vaccine study was paused following a participant's unexplained illness

MARKET WRAP: Sensex slips 171 pts amid weak global cues; RIL up over 2.5%

All that happened in the markets today.

Covid: India leads world in daily tally; resumes more metro lines today

According to the health ministry, Maharashtra, Andhra Pradesh, Karnataka, Uttar Pradesh and Tamil Nadu account for 62% of total active coronavirus cases in the country

US, European Covid-19 vaccine developers pledge to uphold testing rigour

The promise to play by established rules underlines a highly politicised debate over what action is needed to rein in Covid-19 quickly and to jumpstart global business and trade

AstraZeneca Pharma tanks 13% as parent firm halts Covid-19 vaccine trials

The company, which is formulating and testing the vaccine in collaboration with Oxford University, is among the front-runners for last-stage trials of potential virus vaccine

AstraZeneca Covid-19 vaccine study paused after one 'unexplained' illness

Late-stage studies of AstraZeneca's Covid-19 vaccine candidate are on temporary hold while the company investigates whether a recipient's "potentially unexplained" illness is a side effect of the shot

New launches in key categories to trigger AstraZeneca Pharma's growth

Higher share of patented products, scope for margin improvement and chronic portfolio are key positives

AstraZeneca Pharma hits fresh record high of Rs 4,489; stock surges 15%

The stock of the company was trading higher for the fifth straight day, surging 26 per cent during the period.

Astrazeneca to begin Phase 1/2 clinical trials of Covid vaccine in Japan

Astrazeneca said on Friday it is beginning Phase 1/2 clinical trials in Japan of its coronavirus vaccine candidate

AstraZeneca Pharma India hits fresh record high, up 15% in 8 trading days

AstraZeneca Plc, the company's parent firm, is expected to release initial data on whether a vaccine can stop people from getting the virus on September 15

AstraZeneca begins coronavirus vaccine phase 3 clinical trials in US

The phase 3 trial is being implemented as part of Operation Warp Speed, a multi-agency collaboration led by the US Health and Human Services

AstraZeneca's Covid-19 vaccine candidate begins late-stage US study

The trial is being conducted under U.S. government's Operation Warp Speed program, which aims to accelerate development, manufacturing and distribution of vaccines and treatments for Covid-19